News
Pemetrexed and cisplatin is the name of a chemotherapy drug combination. It includes the drugs we list below, next to each drug we have how you pronounce the drug name in brackets. pemetrexed (peh-meh ...
The median OS was not reached at the time of the data cut-off in the pembrolizumab plus chemotherapy arm and was 11.3 months for those in the chemotherapy arm. The Food and Drug Administration ...
Pemetrexed and carboplatin is the name of a chemotherapy combination. It includes the drugs we list below, next to each drug we have how you pronounce the drug name in brackets. You have pemetrexed ...
June 3, 2009 (Orlando, Florida) — Pemetrexed (Alimta, Eli Lilly) following standard chemotherapy improves overall survival in patients with advanced nonsmall-cell lung cancer (NSCLC), according ...
The FDA has been granted to Pemfexy™ (pemetrexed for injection; Eagle Pharmaceuticals), an alternative to Alimta® (Eli Lilly), for the treatment of non-small cell lung cancer (NSCLC ...
Abbreviations: CP, combination of carboplatin and pemetrexed; ORR, overall response rate; OS, overall survival; P, pemetrexed; PFS, progression-free survival. χ 2 test; percentages were calculated ...
A randomized, phase 2 trial of carboplatin plus pemetrexed (Alimta, Eli Lilly) with or without pembrolizumab showed significantly better rates of response and longer progression-free survival with ...
The carboplatin-pemetrexed doublet was well tolerated in the present as well as in the previous studies. [19–21] When comparing the present study with the aforementioned studies, we observe that ...
A single RCT of pemetrexed in MPM was identified. The EMPHACIS ('Evaluation of mesothelioma in a Phase III trial of pemetrexed with cisplatin') study compared pemetrexed plus cisplatin with cisplatin ...
A single RCT of pemetrexed in MPM was identified. The EMPHACIS ('Evaluation of mesothelioma in a Phase III trial of pemetrexed with cisplatin') study compared pemetrexed plus cisplatin with cisplatin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results